Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-09-04Clinical Trial Update: Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
This clinical trial update describes an ongoing study assessing a health technology intervention aimed at improving patient activation in pe…
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: Early Assessment of Cardiac Function After Treatment With CAR-T Cells
A clinical trial update reporting early cardiac function assessment in patients treated with CAR-T cell therapy for hematologic malignancies…
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma [Phase 2]
Phase 2 clinical trial updating on the combination of belantamab mafodotin, pomalidomide, and dexamethasone for high-risk plasma cell myelom…
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM [Phase 1, Phase 2]
This document provides an update on a Phase 1/2 sub-study evaluating belantamab mafodotin in combination with nirogacestat, lenalidomide, an…
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 trial evaluating a dendritic cell/multiple myeloma fusion vaccine in combination with elranatamab for relapsed or refractory multipl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T Cells
This clinical trial update outlines an approach to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation by …
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM [Phase 2]
This clinical trial update describes a Phase 2 study of selinexor in combination with a bispecific antibody (HCMT/MM2401) for relapsed/refra…
-
CLINICAL_TRIALS trial_result · 2025-09-02Clinical Trial Update: Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM [Phase 1, Phase 2]
Clinical trial update for a belantamab mafodotin sub-study in relapsed/refractory multiple myeloma, including monotherapy and combinations w…
-
CLINICAL_TRIALS trial_result · 2025-08-29Clinical Trial Update: A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization [Phase 1]
Completed Phase 1 pharmacodynamic study evaluating the apheresis product from multiple myeloma patients undergoing quad-induction followed b…
-
CLINICAL_TRIALS research · 2025-08-29Clinical Trial Update: Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
A completed Stanford-led clinical trial evaluating wearable sensors and molecular omics approaches to detect and mitigate adverse events dur…
-
CLINICAL_TRIALS research · 2025-08-29Clinical Trial Update: Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) [Phase 2]
A Phase 2 trial (ROTATE) evaluating talquetamab and teclistamab in newly diagnosed multiple myeloma is currently recruiting, aiming to engag…
-
CLINICAL_TRIALS research · 2025-08-29Clinical Trial Update: Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers
Clinical trial is currently recruiting to investigate factors associated with health-related quality of life and social participation in pat…
-
EMA approval · 2025-08-28EMA Authorised: Sarclisa (Isatuximab) — Sanofi Winthrop Industrie
The European Medicines Agency has authorised Sarclisa (isatuximab) for the treatment of multiple myeloma, decision date 18 July 2025.
-
CLINICAL_TRIALS trial_result · 2025-08-28Clinical Trial Update: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies [Phase 1]
The Phase 1 study evaluating AB308 in combination with AB122 in participants with advanced malignancies has been completed.
-
CLINICAL_TRIALS trial_result · 2025-08-28Clinical Trial Update: Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant [Phase 1]
Phase 1 clinical trial evaluating recombinant human interleukin-7 (CYT107) for tumor clearance and immune reconstitution in multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2025-08-27Clinical Trial Update: Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission [Phase 2]
Phase 2 trial update of an allogeneic GM-CSF vaccine with lenalidomide in multiple myeloma patients in complete or near complete remission. …
-
CLINICAL_TRIALS trial_result · 2025-08-26Clinical Trial Update: Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) [Phase 2]
This Clinical Trial Update reports that ipatasertib is being tested as a targeted therapy for cancers with AKT genetic alterations in the NC…
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors [NA]
A Barbara Ann Karmanos Cancer Institute study aims to address social determinants of health among cancer survivors in Metro Detroit and is c…
-
CLINICAL_TRIALS research · 2025-08-24Clinical Trial Update: Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma [Phase 2]
A Phase 2 trial is evaluating the combination of talquetamab and lenalidomide as maintenance therapy after stem cell transplant in multiple …
-
CLINICAL_TRIALS research · 2025-08-24Clinical Trial Update: A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies [Phase 1]
Phase I study to establish safety and maximum tolerated dose of autologous BCMA-targeting CAR T-cells in relapsed/refractory diffuse large B…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure [Phase 2]
Phase 2 trial comparing daratumumab, bortezomib, and dexamethasone versus cyclophosphamide, bortezomib, and dexamethasone in newly diagnosed…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.
This clinical trial update discusses patient perspectives on home-based, subcutaneous Velcade (bortezomib) for multiple myeloma.
-
EMA approval · 2025-08-21EMA Authorised: Ninlaro (ixazomib citrate) — Takeda Pharma A/S
EMA authorised Ninlaro (ixazomib citrate) for the treatment of multiple myeloma. The product has orphan medicine designation and Takeda Phar…
-
CLINICAL_TRIALS research · 2025-08-21Clinical Trial Update: Home Treatment With Carfilzomib in Patients With Multiple Myeloma
A clinical trial update describes home-based treatment with carfilzomib for patients with multiple myeloma, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma [Phase 2]
Phase 2 trial evaluating lenalidomide with or without pomalidomide in combination with dexamethasone for multiple myeloma; the study was ter…